Advertisement
BDTX vs NGEN
Which Stock Would AI Choose? Black Diamond Therapeutics (BDTX) vs. NervGen Pharma (NGEN) Stock Comparison
Key Takeaways
- BDTX is a clinical-stage oncology company focused on a single lead asset, while NGEN is a late-stage neurorepair company advancing a Phase 3 program in spinal cord injury.
- Both companies are pre-revenue biotechs, meaning their valuations hinge on clinical catalysts, cash runway, and regulatory milestones rather than current sales.
- BDTX has reported encouraging Phase 2 lung cancer data but carries meaningful pipeline-concentration risk, whereas NGEN has reached a pivotal Phase 3 stage with prior FDA alignment.
- Relative performance has diverged: NGEN has shown strong one-year gains while pulling back sharply in recent months, while BDTX has traded below its cash value amid a longer-term decline.
- Each name carries distinct binary, event-driven risk profiles tied to clinical readouts and financing needs.
- For more context, explore BDTX Major News and BDTX Today's Price Move, as well as NGEN Major News and NGEN Today's Price Move.
- To see how algorithmic systems are currently positioning across these and thousands of other tickers, explore the curated Trending AI Robots.
Introduction
This comparison examines two clinical-stage biotechnology companies with very different therapeutic mandates: BDTX (Black Diamond Therapeutics), an oncology developer targeting genetically defined cancers, and NGEN (NervGen Pharma), a neurorepair specialist working on spinal cord injury and other neurologic conditions. Both stocks appeal primarily to event-driven and biotech-focused traders and investors who can tolerate elevated volatility and binary clinical outcomes. Because neither company generates product revenue, their market positioning is shaped almost entirely by pipeline progress, cash position, and regulatory catalysts, making a side-by-side review of relative performance and risk essential.
BDTX Overview and Recent Performance
Black Diamond Therapeutics is a clinical-stage oncology company advancing precision medicines that target families of oncogenic mutations. Its lead program, silevertinib, is a brain-penetrant, fourth-generation EGFR (epidermal growth factor receptor) inhibitor in development for EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma. Recent weeks have been shaped by updated Phase 2 data in frontline NSCLC, which reported a 60% overall response rate (ORR), a median progression-free survival (PFS) of 15.2 months, and central nervous system (CNS) activity. The company has also sharpened its focus by out-licensing its BDTX-4933 RAF/RAS program to Servier, leaving silevertinib as its primary wholly owned clinical asset.
Despite positive data, the stock has remained volatile. BDTX has traded below its net cash value and well below prior 52-week highs, reflecting investor concerns about pipeline concentration and competition from established EGFR therapies. The company ended its most recent reported quarter with a cash position it expects will fund operations into the second half of 2028, and it is pursuing a pivotal development path in frontline NSCLC.
NGEN Overview and Recent Performance
NervGen Pharma is a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics. Its lead candidate, NVG-291, is designed to promote nervous system repair and is being evaluated in the Phase 3 RESTORE study for chronic cervical spinal cord injury. Recent market activity has centered on several milestones: alignment with the FDA on the RESTORE trial design, dosing of the first participant, and positive biomechanical gait analysis from the earlier CONNECT SCI study. The company also completed a US$60 million public offering, strengthening its balance sheet into the anticipated data readout.
NGEN has experienced sharp swings, delivering strong one-year gains while declining considerably from its highs in recent months. The company announced a restatement of certain financial statements related to non-cash accounting adjustments for warrants and stock options, which it has said do not affect its cash position or operations. With no commercial revenue, NGEN's stock performance remains tightly linked to execution of its pivotal trial and continued financing discipline.
Trending AI Robots
Tickeron maintains a large library of AI Trading Bots that collectively trade thousands of different tickers across varied strategies, timeframes, and risk profiles. Because not every bot is suited to every market regime, Tickeron curates a dedicated Trending AI Robots section that highlights only the strategies currently best aligned with prevailing market conditions. These bots span a wide range of styles, from short-term momentum and swing approaches to longer-horizon trend-following systems, each with its own performance statistics, historical track record, and set of traded tickers. For traders comparing names such as BDTX and NGEN, these algorithmic tools offer a data-driven complement to manual analysis. Explore the Trending AI Robots page to review the current lineup.
Head-to-Head Comparison
The two companies occupy different corners of biotechnology. BDTX targets precision oncology, competing in a crowded EGFR NSCLC field against entrenched third-generation therapies, while NGEN pursues neurorepair in spinal cord injury, an area with significant unmet need and fewer direct competitors. This difference shapes their growth drivers: BDTX's near-term value depends on durability of its Phase 2 data and a credible pivotal path, whereas NGEN's hinges on successful execution of a registrational Phase 3 trial.
From a momentum perspective, NGEN has delivered stronger one-year relative performance but has experienced deeper recent drawdowns, while BDTX has underperformed over the past year yet trades below cash, which some investors view as a valuation floor. Risk profiles also differ: BDTX faces high pipeline-concentration risk with one lead asset, while NGEN carries binary Phase 3 risk plus recent financial restatement headlines. Sector exposure is biotechnology for both, but oncology and neurotrauma carry different competitive, regulatory, and reimbursement dynamics.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely lean toward the stock demonstrating greater trend consistency and nearer-term catalyst clarity. NGEN's progression to a pivotal Phase 3 study with prior FDA alignment and a completed financing represents a comparatively defined value path, though it remains binary. BDTX offers a compelling valuation-versus-cash setup and positive clinical data, but its single-asset concentration and competitive oncology landscape introduce additional uncertainty. A probabilistic assessment suggests NGEN currently presents the steadier relative positioning, while BDTX may appeal to those seeking a higher-risk, catalyst-driven opportunity tied to lung cancer data and regulatory feedback.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDTX is a Hold and NGEN is a Hold.
BDTX's RSI Indicator ascending out of oversold territory
The RSI Indicator for BDTX moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 29 of the 34 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +12.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDTX advanced for three days, in 199 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDTX as a result. In 60 of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for BDTX turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 38 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
BDTX moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BDTX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BDTX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.037) is normal, around the industry mean (3.498). P/E Ratio (-2.313) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.360) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. BDTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NGEN in -3.65% downward trend, declining for three consecutive days on November 03, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NGEN declined for three days, in 262 of 320 cases, the price declined further within the following month. The odds of a continued downward trend are 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for NGEN entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NGEN's RSI Indicator exited the oversold zone, 29 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for NGEN just turned positive on November 06, 2026. Looking at past instances where NGEN's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
Following a +5.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where NGEN advanced for three days, in 207 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
NGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.277) is normal, around the industry mean (3.498). P/E Ratio (-1.684) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. NGEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BDTX | NGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 61 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 80 | 84 | |
P/E GROWTH RATING 1..100 | 98 | 19 | |
SEASONALITY SCORE 1..100 | 85 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDTX's Valuation (31) in the null industry is somewhat better than the same rating for NGEN (76). This means that BDTX’s stock grew somewhat faster than NGEN’s over the last 12 months.
BDTX's Profit vs Risk Rating (100) in the null industry is in the same range as NGEN (100). This means that BDTX’s stock grew similarly to NGEN’s over the last 12 months.
BDTX's SMR Rating (97) in the null industry is in the same range as NGEN (100). This means that BDTX’s stock grew similarly to NGEN’s over the last 12 months.
BDTX's Price Growth Rating (80) in the null industry is in the same range as NGEN (84). This means that BDTX’s stock grew similarly to NGEN’s over the last 12 months.
NGEN's P/E Growth Rating (19) in the null industry is significantly better than the same rating for BDTX (98). This means that NGEN’s stock grew significantly faster than BDTX’s over the last 12 months.
| BDTX | NGEN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 87% | N/A |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 83% |
| Advances ODDS (%) | 4 days ago 83% | 4 days ago 81% |
| Declines ODDS (%) | 11 days ago 90% | 10 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 78% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDTX’s FA Score shows that 1 FA rating(s) are green while NGEN’s FA Score has 1 green FA rating(s).
- BDTX’s FA Score: 1 green, 4 red.
- NGEN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDTX’s TA Score shows that 3 TA indicator(s) are bullish while NGEN’s TA Score has 5 bullish TA indicator(s).
- BDTX’s TA Score: 3 bullish, 6 bearish.
- NGEN’s TA Score: 5 bullish, 2 bearish.
Price Growth
BDTX (@Biotechnology) experienced а -15.26% price change this week, while NGEN (@Biotechnology) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
BDTX is expected to report earnings on Mar 24, 2027.
NGEN is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, NGEN has been loosely correlated with BDTX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NGEN jumps, then BDTX could also see price increases.
| Ticker / NAME | Correlation To NGEN | 1D Price Change % | ||
|---|---|---|---|---|
| NGEN | 100% | +1.50% | ||
| BDTX - NGEN | 47% Loosely correlated | +0.94% | ||
| MIST - NGEN | 28% Poorly correlated | N/A | ||
| ABEO - NGEN | 27% Poorly correlated | -6.31% | ||
| RCKT - NGEN | 26% Poorly correlated | +1.22% | ||
| PLRX - NGEN | 26% Poorly correlated | -1.03% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RGLO | 32.85 | 0.26 | +0.79% |
| Russell Investments Global Equity ETF (RGLO) | |||
| USVM | 107.23 | 0.67 | +0.62% |
| VictoryShares US Small Mid Cap Value Momentum ETF (USVM) | |||
| FCBD | 24.88 | -0.02 | -0.06% |
| Frontier Asset Core Bond ETF | |||
| CHIQ | 16.19 | -0.23 | -1.37% |
| Global X MSCI China Consumer Discretionary ETF (CHIQ) | |||
| QBTZ | 28.09 | -0.99 | -3.40% |
| Defiance Daily Target 2x Short QBTS ETF (QBTZ) | |||